Page 92 - 《中国药房》2024年15期

康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细

胞肺癌的效果观察
Δ

＊
张晓晓 ，张祉薇，董晓倩，谢曼丽，邓皖利，张 铭（上海中医药大学附属普陀医院中医肿瘤科，上海 200062）

中图分类号 R969.4；R979.1 文献标志码 A 文章编号 1001-0408（2024）15-1882-06
DOI 10.6039/j.issn.1001-0408.2024.15.14

摘 要 目的 观察康莱特注射液辅助卡瑞利珠单抗联合化疗方案治疗晚期非小细胞肺癌（NSCLC）的临床效果。方法 回顾性
选择2018年1月1日至2022年12月1日在我院中医肿瘤科住院治疗的192例晚期NSCLC患者为研究对象，根据患者在卡瑞利珠
单抗联合化疗（卡铂+培美曲塞）方案的基础上是否加用康莱特注射液分为观察组（加用，104例）和对照组（不加用，88例）。对比
两组患者在治疗2、4、6个周期后的近期治疗效果，治疗前、治疗3个周期后、治疗结束时的外周血免疫功能指标和血清肿瘤标志物
水平，以及远期治疗效果和住院治疗期间的不良反应发生情况。结果 在治疗 3 个周期后及治疗结束时，观察组患者外周血中
CD4 T淋巴细胞比例和CD4 /CD8 均明显高于对照组（P＜0.05），血清中癌胚抗原和细胞角质蛋白19片段抗原21-1水平均明显低
+
+
+
于对照组（P＜0.05）；观察组患者的总生存期明显长于对照组（P＜0.05），观察组与对照组患者的中位总生存期分别为（185.27±38.21）、
（132.11±34.23） d；两组患者住院治疗期间出现的总体不良反应及≥3级不良反应比较，差异均无统计学意义（P＞0.05）。结论 在卡瑞
利珠单抗联合化疗方案的基础上加用康莱特注射液可进一步提高晚期NSCLC患者的免疫力，延长患者总生存期。
关键词 康莱特注射液；卡瑞利珠单抗；联合化疗方案；非小细胞肺癌；临床疗效；总生存期

Effect observation of Kanglaite injection assisted with camrelizumab combined with chemotherapy in the
treatment of advanced NSCLC
ZHANG Xiaoxiao，ZHANG Zhiwei，DONG Xiaoqian，XIE Manli，DENG Wanli，ZHANG Ming（Dept. of TCM
Oncology， Putuo Hospital， Shanghai University of Traditional Chinese Medicine， Shanghai 200062， China）

ABSTRACT OBJECTIVE To observe the clinical efficacy of Kanglaite injection assisted with camrelizumab combined with
chemotherapy in the treatment of advanced non-small cell lung cancer （NSCLC）. METHODS A total of 192 patients with
advanced NSCLC and hospitalized in the TCM oncology department of our hospital from January 1st， 2018 to December 1st， 2022
were retrospectively selected as the study objects， and were divided into observation group （additional use， n＝104） and control
group （without additional use， n＝88） according to whether the patients additionally received Kanglaite injection based on
camrelizumab combined with chemotherapy （carboplatin+pemetrexed）. The short-term therapeutic effects of 2，4 and 6 cycles were
compared between the two groups. The levels of peripheral blood immune function indexes and serum tumor markers were
compared before treatment， after 3 cycles of treatment and after treatment. The long-term therapeutic effects as well as the
occurrence of adverse drug reaction（ADR） during hospitalization were compared between the two groups. RESULTS After 3
treatment cycles and at the end of treatment， the CD4 T lymphocyte ratio and CD4 /CD8 in the observation group were notably
+
+
+
greater than the control group （P＜0.05）； the levels of serum carcinoembryonic antigen and cytokeratin 19 fragment antigen 21-1
were significantly lower than those in the control group （P＜0.05）. The overall survival of the observation group was significantly
longer than that of the control group （P＜0.05）， and the median overall survival was （185.27±38.21） d and （132.11±34.23） d，
respectively. There were no significant differences in the whole ADR and grade ≥3 ADR between the two groups during
hospitalization（P＞0.05）. CONCLUSIONS Based on camrelizumab combined with chemotherapy， the addition of Kanglaite
injection can enhance immunological response and prolong overall survival in advanced NSCLC patients.
KEYWORDS Kanglaite injection； camrelizumab； combination chemotherapy； non-small cell lung cancer； clinical efficacy；
overall survival

Δ 基金项目 上海市科技计划项目（No.20Y21900600）；全国（上海
市）名中医普陀传承工作室建设项目（No.ptzygzs2101）；上海市普陀区 肺癌是一种常见的呼吸道恶性肿瘤，在全球范围内
中医临床重点专科建设项目（No.ptzyzk2101）
的恶性肿瘤中最常见且病死率最高，其中非小细胞肺癌
＊第一作者 副主任医师，硕士生导师，硕士。研究方向：中医药防
治恶性肿瘤。E-mail：zxxgoodluck@163.com （non-small cell lung carcinoma，NSCLC）是肺癌的主要

· 1882 · China Pharmacy 2024 Vol. 35 No. 15 中国药房 2024年第35卷第15期